Benefits of Arecor's Arestat™ stabilisation technologies
See also Need for Arecor's technology
Proteins are widely used in medicine, biotechnology, pharmaceuticals and other industries. Stabilisation technologies aim to protect the structure and activity of proteins from degradation in solution or dry phase by temperature change and/or ionising radiation.
Arecor's Arestat™ stabilisation technologies could lead to a number of significant tangible benefits:
To patients
-
Patients could travel with their protein-based medication without the need for refrigeration
-
Drugs could be 'patient-ready' as injectable protein in a pre-filled syringe rather than as a powder for reconstitution
-
Pulmonary-delivered proteins could be formulated as aerosols rather than powders, ensuring better control of dose and less wastage.
To manufacturers
-
Manufacturers could avoid costly freeze-drying to stabilise proteins
-
Proteins could be sterilised at the end of the production process rather than needing to maintain an aseptic production line.
To researchers
- Researchers could develop as drug candidates proteins that would otherwise too unstable.
Benefits of the Arestat™ protein stabilisation technology
-
Arestat™ stabilisation is protein specific – it is based on the unique structure of the protein in question
-
Arestat™ stabilisation involves no covalent modification of the protein - therefore the regulatory approval process is simpler
-
Arestat™ stabilisation involves the use of a panel of generally regarded as safe (GRAS) excipients - so development and regulation is more straightforward
-
Arestat™ stabilisation excipients are readily incorporated into standard manufacturing process.
Last updated: 13 June 2008